Atossa Therapeutics, Inc. (ATOS)
Nasdaq · Healthcare · Biotechnology
$2.45+4.70%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $24.4M
- 52-week range
- $1.70 – $19.35
- 52-week change
- −84.40%
- EPS (trailing)
- −$4.45
- Analyst rating
- 1.5 Strong buy
Fiscal year to Dec 2025
- Net income
- −$34.8M
- Diluted EPS
- −$4.04
- Free cash flow
- −$29.8M
From the company’s annual report on SEC EDGAR.
About Atossa Therapeutics, Inc.
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States. Its lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator and selective estrogen receptor degrader currently in Phase 2 clinical development for the treatment and reduction of risk of breast cancer, as well as in other therapeutic areas. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is based in Seattle, Washington.
Headquarters: Seattle, United States · 16 employees · atossatherapeutics.com